Thought Leadership

It's clear to me that healthcare systems globally – and in the US – will continue to ramp up their scrutiny of the value proposition for new medical technologies. EntityRisk's tools are emerging at just the right time to help companies and patients understand that value.

Healthcare industry leaders, including CFOs, face increased risk when launching new drugs, ranging from challenges in drug pricing and access related to uncertainty in real-world effectiveness, utilization and value.

If a biopharma board isn’t asking ‘how vulnerable are we going to be to policy developments in the U.S. in the next five years,’ then they’re not doing their job. They’re asking many more questions than they were even two or three years ago.

Given its tools, healthcare experience and thought leadership, EntityRisk is well positioned to help leaders mitigate this uncertainty, assess, develop and manage outcomes-based contracts and continue to propel healthcare transformation.